Orforglipron in South Africa: the daily GLP-1 pill explained

What is orforglipron?

Orforglipron is a once-daily weight-management tablet developed by Eli Lilly and sold in the United States as Foundayo. It works on the same GLP-1 receptor as semaglutide and liraglutide, but it is a small molecule rather than a peptide, which is why it needs no food or water rules and no fridge.

The US FDA approved it on 1 April 2026 for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Shipping started within days through Lilly's direct pharmacy channel, with retail pharmacies following shortly after.

Two things make it worth watching from South Africa. It is the first GLP-1 pill approved without restrictions on when or how you take it, and its chemistry suits mass production in a way injectable peptides do not. Lilly has said it filed orforglipron for approval in more than 40 countries.

Is orforglipron available in South Africa?

No. Orforglipron is not registered with SAHPRA, so it cannot legally be sold in South Africa, and no local submission or launch date has been announced. If you searched for Foundayo in South Africa, the position is the same: Foundayo is the US brand name for orforglipron, and neither name is registered here.

The gap is normal rather than a warning sign. Years commonly pass between a first US approval and a South African launch in this class; the Wegovy injection took about four years from its first US approval to reach South African pharmacies.

Until SAHPRA registers it, no pharmacy can stock it and no doctor can include it in a treatment plan. The registered routes for weight management here remain the injectable GLP-1 medicines and orlistat tablets, covered further down this page.

How does orforglipron work?

Orforglipron activates the GLP-1 receptor, the same target semaglutide and liraglutide act on. That reduces appetite, slows stomach emptying and helps regulate blood sugar, so smaller portions satisfy sooner and the constant pull toward food quietens. Our guide to how semaglutide works unpacks the receptor biology the whole class shares.

The chemistry is where orforglipron breaks from the rest. Semaglutide and liraglutide are peptides, chains of amino acids the stomach digests like food, which is why they are injected or, in the Wegovy pill's case, swallowed under strict empty-stomach rules with an absorption enhancer.

Orforglipron is a small molecule, closer in structure to an ordinary tablet medicine. Stomach acid does not destroy it, so it needs no enhancer, no fasting window and no cold chain from factory to bathroom cabinet.

How does orforglipron differ from the Wegovy pill?

Both are once-daily tablets for weight management, and the practical difference sits in the routine. The Wegovy pill is 25 mg of semaglutide taken on an empty stomach with a 30-minute wait before eating or drinking. Orforglipron is taken at any time of day, with or without food.

The two trial averages come from separate studies with different designs and populations, not a head-to-head, and individual results vary. If both tablets eventually register in South Africa, choosing between them will not be the reader's job: the right option is decided by a doctor on assessment.

Full background on the semaglutide tablet, including its own South African status, is in our guide to the Wegovy pill.

How much weight do people lose on orforglipron?

In ATTAIN-1, a 72-week trial of 3,127 adults with obesity, or overweight plus a weight-related condition, and without diabetes, the highest dose of orforglipron produced an average weight loss of 12.4% when taken as intended, against 0.9% on placebo. Individual results vary.

Depth matters as much as the average. On that dose, 59.6% of participants lost at least 10% of their body weight and 39.6% lost 15% or more. Blood pressure and cholesterol improved alongside the weight, and the complete results were published in the New England Journal of Medicine.

A second trial, ATTAIN-2, tested the tablet in 1,613 adults who had type 2 diabetes as well as obesity or overweight. Average weight loss on the highest dose was 10.5% over 72 weeks when taken as intended, against 2.2% on placebo, and HbA1c, the long-term blood sugar measure, fell by 1.8 percentage points. The Lancet published those results, and individual results vary there too.

For context, the pivotal trials of the weekly injections produced higher averages; our semaglutide vs tirzepatide comparison sets those figures out. None of these trial averages is a direct comparison, because each comes from a separate study with its own design.

How is orforglipron taken?

One tablet a day, at any time, with or without food and water. In the United States, treatment starts at 0.8 mg once daily and moves up through 2.5 mg to 5.5 mg at intervals of at least 30 days, with 9 mg, 14.5 mg and 17.2 mg available, each after at least 30 days on the step below, where response and tolerability support it.

The trial publications quote different numbers, 6 mg, 12 mg and 36 mg, because the studies ran on an earlier capsule formulation. The approved 17.2 mg tablet delivers the equivalent of the 36 mg trial capsule, so the two sets of figures describe the same medicine at the same level, not different products.

The slow ladder is deliberate. Stepping up monthly gives the stomach time to adapt, which is how doctors manage the nausea this class commonly causes early on. Storage is simple too: the tablet lives in ordinary packaging at room temperature, with no fridge, no needles and no sharps bin.

What are the side effects of orforglipron?

Mostly stomach-related, matching the rest of the GLP-1 class. In ATTAIN-1, nausea affected 33.7% of people on the highest dose and vomiting 24%, against 10.4% and 3.5% on placebo. Diarrhoea and constipation were also common, mostly mild to moderate and concentrated around dose increases.

Side effects moved some people off treatment: 10.3% of participants on the highest dose stopped because of adverse events, against 2.7% on placebo. That rate shapes real-world results, because a daily tablet only works on the days it is taken.

The class exclusions apply here too. GLP-1 medicines are not used in pregnancy or while breastfeeding, a personal or family history of medullary thyroid cancer or MEN2 syndrome rules the class out, and a history of pancreatitis calls for a careful medical decision. Severe, persistent stomach pain on any GLP-1 medicine can signal pancreatitis: seek medical care immediately.

A tablet carries the same drug class at full strength as the injections, with the same need for a doctor's assessment before starting and follow-up while doses change.

When could orforglipron reach South Africa?

No date exists, because no South African application has been announced. SAHPRA registration starts when the manufacturer files, and neither Lilly nor SAHPRA had communicated an orforglipron submission for South Africa at the time of writing. Lilly's list of more than 40 filing countries has not been published country by country.

Once a file lands, the process has a rough shape. Since SAHPRA cleared its inherited backlog, typical new-medicine turnaround has run around 18 months, and reliance pathways, where SAHPRA builds on completed reviews by regulators such as the FDA, exist to shorten that for well-travelled dossiers.

Registration is also not the finish line. Rybelsus, the semaglutide diabetes tablet, was registered here in 2024 and has still not been launched, so a SAHPRA certificate does not by itself put stock on shelves.

One local fact cuts the other way. Lilly's medicines already reach South Africa through an established channel: Aspen Pharmacare launched Mounjaro in South Africa in partnership with Lilly in December 2024, and SAHPRA added a weight-management registration for tirzepatide in October 2025. A working local partnership shortens the launch step once registration exists, even though it predicts nothing about the filing date.

What would orforglipron cost in South Africa?

There is no South African price for orforglipron, because there is no South African registration. Any rand figure quoted for it today is invented. A local price would only come into existence after SAHPRA registration, when the manufacturer sets a Single Exit Price under the Medicines Act, the system that fixes one national price for every medicine sold in the private sector.

In the United States, Lilly's launch announcement put self-pay pricing at $149 a month for the starting strength, rising with dose, with insured patients paying less through savings cards. Small molecules are cheaper to make and ship than peptides, and simpler manufacturing usually shows up in price once competitors arrive. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

For what registered treatment costs here and now, see GLP-1 treatment costs in South Africa.

Can you buy orforglipron in South Africa now?

No. No South African pharmacy can lawfully stock orforglipron, because SAHPRA has not registered it, and no website or reseller import changes that. Anything offered to South Africans today as orforglipron, Foundayo or a generic GLP-1 pill is an unregistered product with unverified contents.

This is the same territory as the fake semaglutide market. SAHPRA has warned repeatedly about falsified and unregistered GLP-1 products, and enforcement against compounded and copied versions has been active since 2023. An unregistered tablet is a stranger's promise about what is inside it.

When orforglipron is registered here one day, it will sit under the same rules as the rest of the class: a scheduled medicine, a doctor's assessment and authorisation first, then dispensing by a licensed pharmacy. A seller offering to skip those steps is the clearest warning sign you will get.

What weight-loss treatment is registered in South Africa today?

Three GLP-1 medicines carry South African weight-management registrations, all injections: Wegovy (semaglutide), Saxenda (liraglutide) and, since October 2025, Mounjaro (tirzepatide). Ozempic is registered here for type 2 diabetes, not for weight loss. Among tablets, orlistat is the registered weight-loss option.

That short list is the whole registered picture, which is thinner than social media suggests. Our guide to weight-loss pills in South Africa separates the registered tablets from the supplements and unregistered imports sold alongside them.

Which of the registered options fits you, if any, is not decided by which product is newest. A doctor weighs your history, current medicines, side-effect risks and goals, and what to expect from doctor-led weight-loss treatment describes how that assessment runs in practice.

Where does orforglipron fit in the oral GLP-1 pipeline?

Orforglipron is the second weight-management tablet approved in the United States, after the Wegovy pill, and the first built on a small molecule. Behind those two sit further oral candidates in late-stage trials from several manufacturers, so the tablet field will keep widening over the next few years.

The Wegovy pill's own track shows how fast the wave is moving: FDA approval in December 2025, a US launch in January 2026 and European approval by July 2026. Each approval anywhere grows the dossier a manufacturer can bring to SAHPRA.

Competition is already reshaping the class in South Africa. SAHPRA approved the country's first generic semaglutide, for type 2 diabetes, in July 2026, and published prices for the injectable class have fallen since launch. Tablets that are cheaper to manufacture add pressure from another direction.

None of that changes what a South African can do today. Until SAHPRA registers a GLP-1 tablet, every local offer of one is an unregistered product, and the registered treatment conversation starts with a doctor, not a pipeline chart.

Frequently asked questions